The first strategy utilizes the synthetic lethality targeting another remaining DNA repair pathway, e.g. by poly (ADP‐ribose) polymerase inhibitors for treating BRCA1/2‐mutated ovarian cancers 31. This evidence concerns the gene BRCA1 and ovarian cancer.